團隊
Home >> Practices >> Competition and Antitrust >> Katherine Juang
莊郁沁 Katherine Juang

Katherine Juang

Associate Partner

聯絡方式

Katherine Juang is an associate partner at the firm's Corporate and Investment Department and is a core member of the Healthcare & Life Sciences practice groups.

Katherine brings extensive experience in providing comprehensive legal services to clients in the health and life science sector. Her expertise includes legal consultation on risk management and compliance regarding transactions and interaction with health care providers, regulatory matters, data protection, promotional activities, general code of conduct, market access, and negotiation and remedy in reimbursement price disputes. In response to recent developments, Katherine has supported clients in developing strategies to address the evolving landscape of digital health, precision health, and regenerative medicine. She has also represented numerous multinational pharmaceutical companies in patent litigation, unfair competition claims, IP collaboration and licensing negotiations, and patent term extension disputes.

學歷

專業領域

Healthcare & Life Sciences; Data Privacy; Competition Law; Intellectual Property; Product Law; Dispute Resolution

經歷

Group Leader, Healthcare Law Group, Legislation Advisory Committee, Taipei Bar Association
Courses Planning Counselor, Graduate Institute of Health and Biotechnology Law, TMU
Lecturer, Graduate Institute of Health and Biotechnology Law, TMU
Counselor, GMO Food Counselors Commission, Taiwan FDA
Board Director, Taiwan Society for Biopreservation and Biobanking

資格

R.O.C. arbitrator (2019)
Admitted to Taiwan Bar Association (2002)

語言

2023 Court rules in favour of pharmaceutical companies that market category two new drugs
ILO IP Newsletter (20230424)
2023 Taipei High Administrative Court's Latest Ruling: Patent Information of "Category II New Drugs" Allowed to be Submitted in Patent Linkage Registration System
LEXOLOGY
2023 Taipei High Administrative Court's Latest Ruling: Patent Information of "Category II New Drugs" Allowed to be Submitted in Patent Linkage Registration System
LEE & LI Bulletin - January 2023
2023 Summary of Draft Amendment to Rules of Medical Diagnosis and Treatment by Telecommunications announced by Ministry of Health and Welfare
LEE & LI Bulletin -December 2022
2022 Taipei High Administrative Court's Latest Ruling: Patent Information of "Category II New Drugs" Allowed to be Submitted in Patent Linkage Registration System
LEXOLOGY
2022 Constitutional Court Found National Health Insurance Database Lacking Proper Privacy Protection and Ordered Relevant Laws be Amended or New Laws be Promulgated within Three Years
LEXOLOGY
2022 Constitutional Court Found National Health Insurance Database Lacking Proper Privacy Protection and Ordered Relevant Laws be Amended or New Laws be Promulgated within Three Years
LEE & LI Bulletin -October 2022
2022 Constitutional Court Found National Health Insurance Database Lacking Proper Privacy Protection and Ordered Relevant Laws be Amended or New Laws be Promulgated within Three Years
LEXOLOGY
2022 Medical Devices & Consumer Health Products 2022 – Taiwan
Chambers Global Practice Guides: Medical Devices & Consumer Health Products 2022
2022 論標語在我國取得商標保護之阻礙──以識別性為中心
月旦法學326期

More


2023 專題演講:IRPMA Code of Practice 簡介|講師
中華民國開發性製藥研究協會
2023 Regulatory Insights for Regenerative Medicine in Taiwan and Business Shifts | Speaker
Lee and Li, Attorneys-at-Law, ERM Taiwan
回上一頁